Emerald Mutual Fund Advisers Trust Grows Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Emerald Mutual Fund Advisers Trust boosted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 37.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 155,347 shares of the company's stock after buying an additional 42,734 shares during the quarter. Emerald Mutual Fund Advisers Trust owned 0.38% of Keros Therapeutics worth $2,459,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Keros Therapeutics by 5.4% during the 4th quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after buying an additional 100,691 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Keros Therapeutics by 5.5% in the 4th quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock valued at $12,120,000 after purchasing an additional 39,815 shares during the last quarter. Lynx1 Capital Management LP purchased a new stake in shares of Keros Therapeutics in the 4th quarter valued at approximately $8,612,000. American Century Companies Inc. increased its position in shares of Keros Therapeutics by 10.5% in the 4th quarter. American Century Companies Inc. now owns 328,920 shares of the company's stock valued at $5,207,000 after purchasing an additional 31,251 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Keros Therapeutics by 11.3% in the 4th quarter. Northern Trust Corp now owns 296,467 shares of the company's stock valued at $4,693,000 after purchasing an additional 30,111 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KROS. Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Wedbush reaffirmed a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Finally, Piper Sandler dropped their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research report on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Keros Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $40.33.

Insider Transactions at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. This trade represents a 27.01 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 22.90% of the company's stock.

Keros Therapeutics Trading Up 0.9 %

Shares of Keros Therapeutics stock traded up $0.13 on Thursday, reaching $14.57. 689,118 shares of the stock were exchanged, compared to its average volume of 809,280. The firm has a market capitalization of $591.70 million, a PE ratio of -2.80 and a beta of 1.39. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37. The business has a fifty day moving average price of $11.85 and a two-hundred day moving average price of $26.64.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Research analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.